Related Experiment Video
Updated: Feb 6, 2026
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China
Guohai Shi1,2, Sang Hee Park3, Hongye Ren4
1a Department of Urology , Fudan University Shanghai Cancer Center , Shanghai , PR China.
Purpose:
Targeted therapies, including sunitinib, sorafenib, axitinib, and everolimus, have recently become the mainstay for the treatment of metastatic renal cell carcinoma (mRCC). The objective of this study was to estimate the costs of sequential treatment regimens for mRCC and associated adverse events (AEs) from the Chinese payers' perspective.
Methods:
Key inputs included in the calculation were patient population, dosing information, incidence rates and associated costs of Grade 3/4 AEs, treatment costs (including drug discount programs), and patients' progression-free survival (PFS) as a proxy for length of treatment. To calculate PFS, this study identified pivotal clinical trials and generated a reconstructed individual patient data set from the published Kaplan-Meier survival curves. The median PFS from the pooled estimates were used in the calculation. In the base-case scenario, sunitinib was used as first line and the other three therapies were used as second line. Sensitivity analyses were conducted where (1) sorafenib was used as first line, or (2) a third-line therapy was added to the base-case scenario.
Results:
In the base case, the cost per patient per treatment month (PPPM) cost was the lowest for sunitinib + axitinib among all sequential regimens (¥14,898) and was the highest for sunitinib + sorafenib (¥20,103). If sorafenib is used as first line, everolimus had lower per patient per months (PPPM) cost than axitinib (¥17,046 vs ¥23,337), but also had shorter PFS (13.5 months vs 15 months). Second sensitivity analysis with an additional third-line therapy showed consistent results with the base-case scenario; axitinib as second line was the least costly.
Conclusions:
This study demonstrates that, for mRCC sequential treatment, sunitinib followed by axitinib generates the highest cost savings from the Chinese payers' perspective. Future studies are warranted to examine the cost-effectiveness of various mRCC treatment regimens in Chinese populations.
Insights
For metastatic renal cell carcinoma (mRCC) treatment in China, sequential sunitinib followed by axitinib offers the greatest cost savings for payers. This analysis estimated costs for various regimens and adverse events associated with targeted therapies.
Area of Science:
- Oncology
- Health Economics
Background:
- Targeted therapies like sunitinib, sorafenib, axitinib, and everolimus are standard treatments for metastatic renal cell carcinoma (mRCC).
- Estimating the economic impact of sequential treatment regimens is crucial for healthcare payers.
Purpose of the Study:
- To estimate the costs of sequential treatment regimens for mRCC and associated adverse events (AEs) from the perspective of Chinese payers.
- To compare the cost-effectiveness of different first- and second-line targeted therapy combinations.
Main Methods:
- Calculations incorporated patient population, dosing, incidence and costs of Grade 3/4 AEs, and treatment costs, using progression-free survival (PFS) as a proxy for treatment duration.
- PFS was estimated by reconstructing individual patient data from Kaplan-Meier curves of pivotal clinical trials.
- Base-case scenario: sunitinib (first-line) followed by axitinib, sorafenib, or everolimus (second-line). Sensitivity analyses included sorafenib as first-line and addition of a third-line therapy.
Main Results:
- In the base case, sunitinib + axitinib had the lowest cost per patient per treatment month (PPPM) (¥14,898), while sunitinib + sorafenib was highest (¥20,103).
- When sorafenib was first-line, everolimus was less costly than axitinib (¥17,046 vs. ¥23,337 PPPM) but offered shorter PFS (13.5 vs. 15 months).
- Sensitivity analyses, including a third-line therapy, confirmed that axitinib as second-line was the least costly option.
Conclusions:
- Sequential treatment with sunitinib followed by axitinib yields the highest cost savings for Chinese payers in mRCC management.
- Further research is recommended to evaluate the cost-effectiveness of diverse mRCC treatment strategies within the Chinese population.
More Related Videos
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Related Concept Videos
01:15Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
01:24Dosage Regimen: Individualization
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
01:25Dosage Regimen: Multiple Oral Dosage
01:16Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...